Effects of human atrial natriuretic peptide in patients after coronary artery bypass surgery

What Was Tested

Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

To determine the effects of synthetic human atrial natriuretic peptide (ANP) on renal function, hemodynamics, and levels of vasoactive peptides when infused in the immediate postoperative period after coronary bypass surgery in patients with normal kidney function.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The Department of Cardiothoracic Anaesthetics and Intensive Care of a university hospital.

Thirty patients with normal kidney function scheduled for elective coronary bypass surgery.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

The comparison arm used a placebo, so changes seen with ANP (Atrial Natriuretic Peptide) could be set against what happens without it.

A prospective, randomized, double-blind, placebo-controlled study.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Coronary Artery Bypass, Glomerular Filtration Rate, Hemodynamics and Kidney.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1996 (Journal of cardiothoracic and vascular anesthesia), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.